A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions
Relapse-Remitting Multiple Sclerosis
Interventions
DRUG

glatiramer acetate 20 mg

glatiramer acetate 20 mg

DRUG

glatiramer acetate 40 mg

glatiramer acetate 40 mg

Trial Locations (20)

10029

MSSM - Corinne Goldsmith Dickinson Center for MS, New York

14642

University of Rochester, Rochester

15212

Allegheny Neurological Associates, Pittsburgh

17822

Geisinger Medical Center, Danville

38163

University of Tennessee, Memphis

44195

Cleveland Clinic Foundation, Cleveland

46202

Indiana University School of Medicine, Indianapolis

48334

Michigan Institute of Neurological Disorders, Farmington Hills

55422

The Minneapolis Clinic of Neurology, LTD, Golden Valley

55455

University of Minnesota, Minneapolis

60062

Consultants in Neurology, Ltd, Northbrook

63141

St. John's Mercy Medical Center, St Louis

84148

VAMC, Salt Lake City

87131

Clinical & Magnetic Resonance Research Ctr., Albuquerque

92037

Center for Neurologic Study, La Jolla

92056

North County Neurology Associates, Oceanside

98101

MS Hub Medical Group, Seattle

98405

Neurology & Neurosurgery, Tacoma

Unknown

The MS Center of Atlanta, Atlanta

The Maryland Center for M.S., Baltimore

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00202982 - A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose | Biotech Hunter | Biotech Hunter